What drove the significant revenue growth in the quarter?

Revenue growth was primarily driven by the U.S. Pharmaceutical segment, which saw an 18% increase. This growth was attributed to market expansion, higher volumes from retail national account customers, strong performance in specialty pharmaceuticals, and price increases for branded drugs, partially offset by generic drug conversions.

How is McKesson managing its expenses and profitability?

McKesson effectively managed its expenses, with total operating expenses decreasing by 3% year-over-year. This was achieved through a 5% reduction in Selling, Distribution, General, and Administrative (SDG&A) expenses, partly due to the divestiture of European businesses. Despite a flat gross profit, these expense controls led to a substantial increase in operating income and net income.

What is the company's strategy regarding capital allocation and shareholder returns?

McKesson is actively returning capital to shareholders. In the quarter, $770 million was returned through share repurchases ($696 million) and dividends ($74 million). The company also announced an increase in its quarterly dividend to $0.62 per share and approved a significant $6.0 billion increase in its share repurchase authorization, indicating a strong commitment to enhancing shareholder value.

What is the company's exposure to litigation, particularly concerning opioid claims?

McKesson remains a defendant in numerous opioid-related litigation cases, with an estimated total accrued liability of $7.2 billion as of June 30, 2023. While the company has entered into settlement agreements with many governmental entities, it continues to defend against other claims. The company has paid $529 million in July 2023 related to settlements. While these liabilities are significant, the company believes it has valid legal defenses for claims not covered by settlements.

MCK 10-Q Quarterly Report Q1 FY2024 — Revenue, Net Income, EPS

Summary

McKesson Corporation (MCK) reported strong revenue growth of 11% year-over-year for the quarter ending June 29, 2023, reaching $74.5 billion. This increase was primarily driven by robust performance in the U.S. Pharmaceutical segment, benefiting from market growth, higher volumes, and specialty pharmaceutical expansion. Despite flat gross profit, operating expenses saw a 3% decrease, contributing to a significant 24% rise in income from continuing operations to $997 million. Diluted earnings per share (EPS) from continuing operations also saw a substantial increase, growing by 34% to $7.02. The company demonstrated effective capital management, returning $770 million to shareholders through $696 million in stock repurchases and $74 million in dividends. Management also announced an increase in the quarterly dividend and a significant expansion of its share repurchase authorization, signaling confidence in future financial performance. While the company faces ongoing litigation, particularly related to opioid claims, the overall financial health appears solid, supported by consistent revenue generation and disciplined expense management.

Financial Highlights

52 data points

Beta

Revenue

$74.48B

0.0% Gross Margin

Net Income

$958.00M

0.0% Net Margin

EPS (Diluted)

$7.02

Total Assets

$64.10B

Cash & Equivalents

$2.64B

Free Cash Flow

-$1.13B

Financial Statements

Beta

Revenue	$74.48B
Cost of Revenue	$71.46B
Gross Profit	$3.02B
SG&A Expenses	$1.87B
Operating Expenses	$1.92B
Operating Income	$1.10B
Interest Expense	$47.00M
Net Income	$958.00M
EPS (Basic)	$7.07
EPS (Diluted)	$7.02
Shares Outstanding (Basic)	135.50M
Shares Outstanding (Diluted)	136.60M

Key Highlights

1Revenues increased by 11% year-over-year to $74.5 billion, driven by the U.S. Pharmaceutical segment.
2Income from continuing operations rose 24% to $997 million.
3Diluted EPS from continuing operations grew 34% to $7.02.
4Total operating expenses decreased by 3%, indicating effective cost management.
5The company returned $770 million to shareholders via dividends and share repurchases.
6A net discrete tax benefit of $147 million was recognized related to intellectual property repatriation.
7McKesson completed a $1 billion debt offering and used proceeds to repurchase outstanding notes.

MCKESSON CORP Quarterly Report for Q1 Ended Jun 30, 2023

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions